sysa1801
torl biotherapeutics,context therapuetics,cspc pharmaceuticals,elevation oncology
['up next', 'gastric', 'torl,1,23', '$cntx']
$elev claudin18.2 adc is active and safe at 1/2.0/2.5mg/kg orr 47% in gastric cancer $86m mc with $74m cash and us ph1 starts 2h23 torl biotherapeutics claudin6 adc up next
$cntx #asco23 